Figure 6.

The E-cadherin-GFP Mouse as a Tool to Monitor the Early Anti-invasive Drug Response

(A) Schematic of anti-invasive dasatinib treatment using Kras^G12D; p53^R172H; E-cadherin-GFP mice.

(B) Representative images from confocal FRAP movies of dasatinib-treated Kras^G12D; p53^R172H; E-cadherin-GFP mouse (oral gavage, 3× daily, 10 mg/kg). Red arrows, bleached regions.

(C and D) Graphs comparing E-cadherin-GFP mobilization in in situ pancreatic tissue of control (orange) and dasatinib-treated (pink) Kras^G12D; p53^R172H; E-cadherin-GFP mice. Columns, mean; bars, ± SE; n = 3 mice/group, ≥21 junctions in total. ^∗∗p < 0.01 (unpaired Student’s t test).

(E and F) TEER (E) and Dispase assays (F) in E-cadherin-GFP-transfected p53^−/− PDAC cells (columns 1 and 3, pre-dasatinib; columns 5 and 7, post-dasatinib) versus mutant p53 PDAC cells (columns 2 and 4, pre-dasatinib; columns 6 and 8, post-dasatinib). Columns, mean; bars, ± SE; n = 3 mice/group. ^∗p < 0.05; ^∗∗p < 0.01 (unpaired Student’s t test).

See also Figure S4.